Healthcare
Polarean Imaging plc(PLLWF)
Live Price
Offline$0.0066
+0.00% today
1Y Change
-40.00%
Window
Jun 23, 2025 → Jun 10, 2026
- Market Cap
- —
- Revenue Growth
- +246.8%
- EPS Growth
- +87.2%
- Dividend Yield
- 0.0%
Coverage: 249 bars · Jun 23, 2025 → Jun 10, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Polarean Imaging plc (PLLWF) is a Healthcare stock with listed on OTC. The stock last traded around $0.01 and down 40.0% across the available one-year price window (Jun 23, 2025 → Jun 10, 2026). Baseline metrics include revenue growth of +246.8%, EPS growth of +87.2%, a dividend yield of 0.0%. What stands out right now is revenue +246.8%, EPS +87.2%, free cash flow +44.8% with operating margin -390.0% and ROIC -91.7%. Valuation is more restrained than many high-expectation growth names at price/sales 0.7. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines PLLWF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+246.8% vs +7.6% peer median
Operating Margin
Below sector median
-390.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
The operating story is still moving forward
Revenue is running at +246.8% and EPS at +87.2%, with operating margin around -390.0%.
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PLLWF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
PLLWF Max Drawdown
-90.91%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for PLLWF and SPY.
Company Overview
Polarean Imaging plc
Other OTC
Polarean Imaging plc operates as a medical drug-device combination company serving the medical imaging market in the United States, Canada, Germany, and the United Kingdom. The company engages in the development and commercialization of gas polarizer devices and ancillary instruments. It develops equipment that enables existing magnetic resonance imaging (MRI) systems to achieve a level of pulmonary functional imaging and specializes in the use of hyperpolarized xenon gas (129Xe) as an imaging agent to visualize ventilation and gas exchange regionally in the smallest airways of the lungs, the tissue barrier between the lung and the bloodstream, and in the pulmonary vasculature; and a novel diagnostic approach. The company is also involved in the development and manufacture of MRI radiofrequency coils, which are required components for imaging 129Xe in the MRI system. Polarean Imaging plc was incorporated in 2016 and is based in Durham, North Carolina.
- Leadership
- Christopher Richard Von Jako
- IPO Date
- Oct 2, 2018
- Employees
- 29
- Street Address
- 2500 Meridian Parkway
- Mailing
- London, NC, 27713
- Region
- London, NC, US
- Reporting Currency
- USD
- Investor Line
- 919 206 7900
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- —
- EV/EBITDA
- 0.8
- Price/Sales
- 0.7
- Price/Book
- 0.2
Growth
- Revenue
- +246.8%
- EPS
- +87.2%
- Free Cash Flow
- +44.8%
Profitability
- Gross Margin
- 16.4%
- Operating Margin
- -390.0%
- Net Margin
- -373.6%
- ROE
- -74.0%
- ROIC
- -91.7%
Balance Sheet
- Debt/Equity
- 0.06
- Current Ratio
- 3.56
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.